Nutriband to Present AVERSA Technology Strategy at MicroCap Rodeo Conference

Nutriband Inc. (NASDAQ: NTRB) has announced its participation in the upcoming MicroCap Rodeo Conference scheduled for September 25, 2025, in New York City. The company's Chairman Serguei Melnik will deliver a presentation at 10 a.m. focusing on operational highlights, growth initiatives, and the strategic direction for its proprietary AVERSA platform technology. This presentation will be webcast live, with registration available for interested parties through the conference platform.

The conference appearance represents a significant opportunity for Nutriband to showcase its innovative AVERSA technology, which is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company's primary development focus is on an abuse-deterrent fentanyl patch that incorporates this proprietary technology. The AVERSA platform can be integrated into any transdermal patch formulation, positioning Nutriband at the forefront of addressing the ongoing opioid crisis through technological innovation.

Investors and industry observers can access additional information about Nutriband's developments through the company's dedicated newsroom available at https://ibn.fm/NTRB. The MicroCap Rodeo Conference serves as an important venue for emerging companies to connect with the investment community and discuss their growth trajectories. Nutriband's participation underscores the company's commitment to transparency and investor communication as it advances its pharmaceutical development programs.

The presentation will provide insights into how Nutriband plans to leverage its AVERSA technology across multiple pharmaceutical applications. The technology's ability to be incorporated into various transdermal delivery systems represents a substantial market opportunity in the abuse-deterrent drug formulation space. As regulatory agencies continue to emphasize the importance of abuse-deterrent properties in controlled substance medications, Nutriband's technology platform positions the company to potentially address significant unmet needs in pain management and addiction prevention.

Additional details about the conference and presentation logistics are available through the official event channels. The webcast availability ensures broader access for stakeholders unable to attend the New York event in person. This presentation follows Nutriband's ongoing development efforts and represents an important milestone in the company's communication strategy with the investment community.